Global Nuclear Medicine/Radiopharmaceuticals Market 2015-2020 - Potential Radioisotopes In The Pipeline a Huge Opportunity

Jul 21, 2015, 13:13 ET from Research and Markets

DUBLIN, July 15, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/5bvmb7/nuclear) has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020" report to their offering.

The global radiopharmaceuticals market is expected to reach $6.96 Billion by 2020 from $4.50 Billion in 2015, growing at a CAGR of 9.1% from 2015 to 2020.

Nuclear medicine/radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in the nuclear imaging field to diagnose and treat diseases. The radiopharmaceuticals market is bifurcated into diagnostics and therapeutics segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET; whereas, radiopharmaceuticals in the therapeutics market are categorized as beta emitters, brachytherapy isotopes, and alpha emitters.

The global radiopharmaceuticals market is segmented on the basis of type, application, and region. Based on type, the nuclear medicine market is categorized into diagnostics and therapeutics segments. In 2014, the diagnostics segment accounted for the largest share of the nuclear medicine market. The diagnostics segment is further segmented into SPECT and PET. In 2014, the SPECT segment accounted for the largest share of the radiopharmaceuticals diagnostics market. The therapeutics segment is further segmented into beta emitters, alpha emitters, and brachytherapy isotopes. In 2014, the beta emitters segment accounted for the largest share of the radiopharmaceuticals therapeutics market.

Based on applications, the nuclear medicine market is segmented into diagnostics (SPECT and PET) and therapeutics applications. In 2014, the diagnostics segment accounted for the largest share of the nuclear medicine market.

Factors such as advances in radiotracers, alpha radio immunotherapy-based targeted cancer treatment, and increasing number of patients with cancer and cardiovascular aliments are driving the growth of this market. Moreover, potential radioisotopes in the pipeline, high demand from emerging countries, and advances in neurological applications are likely to create huge opportunities for this market in the coming years. However, factors such as shorter half-life of radiopharmaceuticals, stringent regulatory guidelines, and competition from conventional diagnostic procedures are hindering the growth of this market.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Global Nuclear Medicine/Radiopharmaceuticals Market, By Type

7 Global Nuclear Medicine/Radiopharmaceuticals Market, By Procedural Volume

8 Global Nuclear Medicine/Radiopharmaceuticals Market, By Application

9 Global Nuclear Medicine/Radiopharmaceuticals Market, By Region

10 Competitive Landscape

11 Company Profiles

- Advanced Accelerator Applications S.A. - Bayer Healthcare - Bracco Imaging - Cardinal Health, Inc. - Eczacibasi-Monrol Nuclear Products - Ge Healthcare - IBA Molecular Imaging - Lantheus Medical Imaging - Mallinckrodt Plc - Nordion, Inc.

For more information visit http://www.researchandmarkets.com/research/5bvmb7/nuclear

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

 



SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com